AlgiPharma announces the appointment of Dr. Preston W. Campbell MD to the Board

/in

We are extremely pleased to announce the appointment of Preston W. Campbell to the AlgiPharma Board as a non-executive Board Member. His experience and wisdom will be invaluable in guiding the AlgiPharma team and their alginate technology closer to market.

 

Dr. Preston Campbell served at the Cystic Fibrosis Foundation for 25 years where he focused on Cystic Fibrosis (CF) drug discovery and development. After a successful career as a Pediatric Pulmonologist at Vanderbilt University, he joined the Foundation as Executive Vice President of Medical Affairs in 1998. In 2015, he became the Foundation’s President and CEO. During his tenure at the Foundation, he oversaw the Foundation’s research initiatives and its collaborative drug discovery and development program. He has extensive experience with numerous companies helping them navigate discovery or clinical development efforts. These resulted in the approval of twelve CF therapies including four that treat the basic defect in CF. The most recent was Trikafta, which benefits 93 percent of people with the disease. The survival of people with CF during this time has increased dramatically. He retired in 2023 and remains involved with drug discovery and development as an independent consultant. He is a citizen of the United States of America.

 

About AlgiPharma AS:

AlgiPharma AS is a clinical stage pharmaceutical company, founded in 2006 on decades of research and development carried out by FMC BioPolymer AS and the Institute of Biotechnology at the Norwegian University of Science and Technology (NTNU) in Trondheim, Norway. AlgiPharma has completed 5 clinical trials with two formulations of its lead drug candidate, OligoG, to treat respiratory symptoms of cystic fibrosis. AlgiPharma is developing its proprietary alginate technology for:

  • Delivery platforms for nanoparticles, small and large molecule based drugs.
  • Drug conjugates, adding functionality and reducing toxicity of parent compound.
  • API in disease areas such as cystic fibrosis, COPD, and infectious diseases.

AlgiPharma has pharmaceutical scale production capabilities for its technology protected by a broad family of patents.

AlgiPharma owns or licenses all relevant patents upon which the technology platform and products are developed. The company is supported by national and international research programs, and collaborates with a network of key opinion leaders, highly recognized academic institutions, research and patient organizations in Europe and USA.

AlgiPharma has received more than USD 46 million in research and development grants from EU’s 7th framework program, Horizon 2020, and Eurostars programs, the Norwegian Research Council, Innovate UK, Innovation Norway, US Army through Congressional Earmark funding, the Australian R&D Tax Incentive, and the Cystic Fibrosis Foundation (CFF).

AlgiPharma is a privately owned company registered and domiciled in Norway.

For additional information contact:

Yngvar P. Berg, CEO: yngvar.berg@algipharma.com

Arne Dessen, COO and Chairman of the Board: arne.dessen@algipharma.com